Sing-Yuen Sit
Inventor
Stats
- 46 US patents issued
- 66 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 46 US Patents Issued
- 66 US Applications Filed
- 434 Total Citation Count
- Oct 28, 2024 Most Recent Filing
- Feb 18, 1988 Earliest Filing
Work History
Patent Owner | Applications Filed | Year |
---|---|---|
BRISTOL-MYERS COMPANY | 1
| 1988
|
VIIV HEALTHCARE UK (NO.5) LIMITED | 4
2 4 2 3 | 2011
2012 2013 2014 2015 |
VIIV HEALTHCARE UK (NO. 4) LIMITED | 2
1 2 2 1 | 2012
2014 2015 2016 2017 |
PURDUE RESEARCH FOUNDATION | 1
1 | 2002
2003 |
BRISTOL-MYERS SQUIBB COMPANY | 4
3 2 2 1 1 2 1 4 1 2 4 1 2 2 2 1 1 2 1 | 1988
1989 1990 1991 1992 1997 1998 2000 2001 2002 2003 2004 2005 2007 2008 2010 2012 2013 2014 2015 |
VIIV HEALTHCARE (NO. 4) LIMITED | 2
1 2 1 | 2012
2014 2015 2016 |
Inventor Addresses
Address | Duration |
---|---|
MERIDEN, CT, US | Oct 10, 13 - Oct 10, 13 |
Meriden, CT | Sep 26, 89 - Nov 11, 08 |
Meriden, CT, US | Nov 05, 09 - Mar 06, 25 |
Meridian, CT, US | Dec 01, 22 - Dec 24, 24 |
Wallingford, CT, US | Oct 26, 17 - Oct 21, 21 |
Technology Profile
Technology | Matters | |
---|---|---|
A01N: | PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF | 1 |
A61K: | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | 37 |
A61P: | THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS | 14 |
Patents / Publication
Patents / Publication # | Year of Publication / Issued | Title | Citations |
---|---|---|---|
2025/0074,909 | 2025 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | 0 |
12172975 | 2024 | 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1) | 0 |
12157733 | 2024 | Aminotriazolopyridines as kinase inhibitors | 0 |
11618753 | 2023 | Aminopyrrolotriazines as kinase inhibitors | 0 |
2022/0380,335 | 2022 | 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) | 2 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.